Article
#ASH20 UPDATED: In a multiple myeloma showdown, Regeneron marches out new PhI data for its BCMA bis
Rating:
0.0
Views:
85
Likes:
1
Library:
1
After kicking off a multiple myeloma rivalry with Bristol Myers Squibb at last year's ASH, Regeneron is back with an updated safety and durability analysis from the first-in-human study of its BCMA bispecific. In the Phase I portion of a Phase I/II dose-escalation study, researchers noted a 6-month median duration
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value